We conducted this meta-analysis on all published RCTs data to systematically evaluate the therapeutic efficacy and safety of approved anti-PD-1 medications in patients with advanced ESCC refractory or intolerant to first-line regimens. Here, PDCD1 is linked to esophageal squamous cell carcinoma.